

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT ON SPECIAL DIVIDEND

Reference is made to the prospectus of China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 17 October 2016 (the “**Prospectus**”) in relation to, among other things, a special pre-listing dividend distribution plan of the Company (the “**Special Dividend**”).

As disclosed in the Prospectus, CRH (Pharmaceutical) Limited (“**CRH (Pharmaceutical)**”), Beijing Pharmaceutical Investment Limited (“**Beijing Pharmaceutical Investment**”) and Beijing Equity Investment Development Fund (Cayman II) L.P., being the then shareholders of the Company prior to the listing of the Company, approved the Special Dividend on 9 October 2016 (the “**Special Dividend Shareholders’ Resolution**”), pursuant to which the Company is required to distribute the Special Dividend of approximately HK\$2,227.8 million from its consolidated retained earnings as of 30 June 2016 to CRH (Pharmaceutical) and Beijing Pharmaceutical Investment in the proportion of 72% and 28%, respectively, within 24 months from the listing date of the Company.

As disclosed in the Prospectus, shareholders of the Company (other than CRH (Pharmaceutical) and Beijing Pharmaceutical Investment) are not entitled to the Special Dividend.

The board of directors (the “**Board**”) of the Company hereby announces that, taking into account the distributable profits attained by the Company, the Board has resolved to declare the Special Dividend in the amount of HK\$668,348,317.93, representing a total of 30% of the Special Dividend, of which HK\$481,210,788.91 and HK\$187,137,529.02 will be distributed to CRH (Pharmaceutical) and Beijing Pharmaceutical Investment in the proportion of 72% and 28%, respectively, pursuant to the Special Dividend Shareholders’ Resolution. It is expected that such Special Dividend will be paid to CRH (Pharmaceutical) and Beijing Pharmaceutical Investment by 22 December 2017, and the payment of such Special Dividend will be funded by cash resources of the Group, including distributions from the subsidiaries of the Company and external financing (other than the net proceeds from the Global Offering of the Company).

It is expected that the remaining 70% of the Special Dividend in an aggregate amount of HK\$1,559,479,408.50 will be paid to CRH (Pharmaceutical) and Beijing Pharmaceutical Investment in the proportion of 72% and 28%, respectively, by no later than 28 October 2018 pursuant to the Special Dividend Shareholders’ Resolution.

By order of the Board
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Hong Kong, 12 December 2017

As of the date of this announcement, the Board comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng, Mr. SONG Qing and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang, Mr. WANG Chenyang and Ms. WANG Jing as non-executive Directors, Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.